Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT?

Mohammad A Rafi ¹ * , Paola Luzi ¹, David A Wenger ¹

Cited by CrossRef: 8

1- Feltri M, Weinstock N, Favret J, Dhimal N, Wrabetz L, Shin D. Mechanisms of demyelination and neurodegeneration in globoid cell leukodystrophy. Glia. 2021;69(10):2309 [Crossref]

2- Hordeaux J, Jeffrey B, Jian J, Choudhury G, Michalson K, Mitchell T, Buza E, Chichester J, Dyer C, Bagel J, Vite C, Bradbury A, Wilson J. Efficacy and Safety of a Krabbe Disease Gene Therapy. Human Gene Therapy. 2022;33(9-10):499 [Crossref]

3- Gupta A, Raymond G, Pierpont E, Kemp S, McIvor R, Rayannavar A, Miller B, Lund T, Orchard P. Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy. Expert Opinion on Biological Therapy. 2022;22(9):1151 [Crossref]

4- Wenger D, Luzi P, Rafi M. Advances in the Diagnosis and Treatment of Krabbe Disease. IJNS. 2021;7(3):57 [Crossref]

5- Nowacki J, Fields A, Fu M. Emerging cellular themes in leukodystrophies. Front Cell Dev Biol. 2022;10 [Crossref]

6- Heller G, Bradbury A, Sands M, Bongarzone E. Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases. Molecular Therapy. 2023;31(1):7 [Crossref]

7- LeVine S, Tsau S. Substrate Reduction Therapy for Krabbe Disease: Exploring the Repurposing of the Antibiotic D-Cycloserine. Front Pediatr. 2022;9 [Crossref]

8- Herdt A, Peng H, Dickson D, Golde T, Eckman E, Lee C. Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease. Genes. 2023;14(8):1517 [Crossref]

9- Maghazachi A. Globoid Cell Leukodystrophy (Krabbe Disease): An Update. ITT. 2023;Volume 12:105 [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons